Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.59 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.59 |
| ▸ | TAOK3 | Q9H2K8 | 4/20 | 0.44 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 11/20 | 0.41 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.41 |
| ▸ | IDE | P14735 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MC1R | Q01726 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22677598 | 0.98 | KDM1A (0.59) | KDM1ARCOR1TAOK3TAOK1PSMB5 | |
| SCHEMBL22677624 | 0.98 | KDM1A (0.59) | KDM1ARCOR1TAOK3TAOK1PSMB5 | |
| SCHEMBL22677596 | 0.94 | KDM1A (0.54) | KDM1ARCOR1TAOK3TAOK1PSMB5 | |
| SCHEMBL22677609 | 0.90 | KDM1A (0.61) | KDM1ARCOR1IDEMC4RMC1R | |
| SCHEMBL22677646 | 0.90 | KDM1A (0.61) | KDM1ARCOR1IDEMC4RMC1R | |
| SCHEMBL22678362 | 0.88 | KDM1A (0.63) | KDM1ARCOR1TAOK3TAOK1IDE | |
| SCHEMBL22677636 | 0.88 | KDM1A (0.63) | KDM1ARCOR1TAOK3TAOK1IDE | |
| SCHEMBL22677571 | 0.86 | KDM1A (0.70) | KDM1ARCOR1PSMB5PSMB2IDE | |
| SCHEMBL22677568 | 0.86 | KDM1A (0.70) | KDM1ARCOR1PSMB5PSMB2IDE | |
| SCHEMBL22677517 | 0.86 | KDM1A (0.73) | KDM1ARCOR1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279733-B2 | Peptide antibiotics | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-22 | — | — | US | disclosed |
| US-20200361994-A1 | PEPTIDE ANTIBIOTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361994-A1 | PEPTIDE ANTIBIOTICS | NGLY1, VIP, PEPD | KDM1A 4796/4885RCOR1 4836/4885TAOK3 1395/4885 |
| US-11279733-B2 | Peptide antibiotics | NGLY1, VIP, PEPD | KDM1A 4796/4885RCOR1 4836/4885TAOK3 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.